Pfizer, the world’s largest drug maker, announced that it paid about $20 million to 4,500 doctors and other medical professionals for consulting and speaking on its behalf in the last six months of 2009. Pfizer also paid $15.3 million to 250 academic medical centers and other research groups for clinical trials in the same period. The announcements are Pfizer's first public accounting of payments to the people who decide which drugs to recommend, the New York Times reports.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
